Precision BioSciences has appointed Michael Amoroso to be its new president and CEO, as the US biotech looks ahead to the regulatory and commercial challenges of bringing its off-the-shelf CAR-Ts and gene-editing therapies to market.
Amoroso is jumping ship to Precision just six months after being promoted to the role of CEO at another gene...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
